Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Expected To File Second Anti-Generic Suit In India

This article was originally published in PharmAsia News

Executive Summary

Roche is stepping up its legal fight against India's Cipla over the latter's attempts to market a generic of Valcyte (valganciclovir) for treating HIV/AIDS infections. Roche is expected to intensify the fight by filing in the Madras high court, adding to its legal efforts against Cipla. Another suit already has been filed in the Delhi high court, seeking an injunction against Cipla on grounds its generic infringes on the patent for Tarceva (erlotinib), Roche's anti-cancer drug. The Valcyte suit is expected to be filed in the Madras court because it was patented in the Chennai patent office. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts